Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
amivantamab
(a-mih-VAN-tuh-mab)Other Names
Rybrevant®
Appearance
pale yellow liquid mixed into larger bags of fluids
Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Drug Monograph
Nov 2025
Eligibility forms
- Amivantamab - In Combination with Chemotherapy for EGFR-mutated Advanced NSCLC after Osimertinib Treatment
- Amivantamab - In Combination with Chemotherapy for First-line Treatment of Advanced NSCLC with Exon 20 Insertion Mutations
- Amivantamab - In Combination with Lazertinib for First-line Treatment of EGFR-mutated Advanced NSCLC
- Amivantamab - Previously Treated Advanced or Metastatic NSCLC with Exon 20 Insertion Mutations
Patient Info sheet
Nov 2025
What it is used for: For treat certain types of breast cancer
You might be also interested in
Discuss with the content team about the section below.
XXXX
XXXX
XXXX
Last Updated: October 02, 2026
